Evidence map›Paper›PMID 39836306›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Rapid fabrication and dissolution of pressed

Jonathan Siikanen, Stefan Milton, Klas Bratteby, Wilson Lin, Jonathan W Engle, Emma Jussing, Thuy A Tran

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Emerging Theranostic Radiometals (Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jonathan SiikanenDepartment of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, 171 76, Sweden. Jonathan.siikanen@ki.se.ORCID http://orcid.org/0009-0006-6568-4601
Stefan MiltonDepartment of Clinical Neurosciences, Karolinska Institutet, Stockholm, 171 77, Sweden.
Klas BrattebyDepartment of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, 171 76, Sweden.
Wilson LinDepartment of Medical Physics, University of Wisconsin, 1111 Highland Ave, Madison, WI, 53705, USA.
Jonathan W EngleDepartment of Medical Physics, University of Wisconsin, 1111 Highland Ave, Madison, WI, 53705, USA.
Emma JussingDepartment of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, 171 76, Sweden.
Thuy A TranDepartment of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, 171 76, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeyond the use of conventional short-lived PET radionuclides, there is a growing interest in tracking larger biomolecules and exploring radiotheranostic applications. One promising option for imaging medium-sized molecules and peptides is ⁵⁵Co (T₁/₂ = 17.5 h, β⁺ = 76%), which enables imaging of new and already established tracers with blood circulation of several hours. Additionally, ⁵⁵Co can be paired with the Auger-Meitner emitter

resultsThis set up is capable to produce and isolate 240 ± 20 MBq [

conclusionWe present a novel, simple, and rapid method to produce ⁵⁵Co with pressed ⁵⁸Ni/Mg matrix targets enabling faster target fabrication and dissolution. By using a simple hydraulic press, mechanically stable target coins useful for solid target irradiation are fabricated within 5 min and can be dissolved in 10 min at room temperature. The foils remain intact after irradiation and can endure irradiation conditions providing sufficient activity (> 200 MBq) for clinical doses. The method presented here using Mg as a support metal for fixation of the actual target material into target coins is applicable for other target combinations as well. Using Mg as a support metal is suitable due to its thermal conductivity, low activation, minimal impact on purification chemistry, softness, ductility, and rapid dissolution in acid.

Indexed as

55Co 58Ni/Mg-matrixAMACyclotronDOTASolid target

Identifiers

PMID39836306
PMCPMC11751214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.